Details

Autor(en) / Beteiligte

• Wedzicha, Jadwiga A
• Banerji, Donald
• Chapman, Kenneth R
• Vestbo, Jørgen
• Roche, Nicolas
• Ayers, R. Timothy
• Thach, Chau
• Fogel, Robert
• Patalano, Francesco
• Vogelmeier, Claus F

Titel

Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD

Ist Teil von

• The New England journal of medicine, 2016-06, Vol.374 (23), p.2222-2234

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2016

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• This randomized trial compared a long-acting beta-agonist (LABA) plus a glucocorticoid with a LABA plus a long-acting muscarinic antagonist for preventing exacerbations of chronic obstructive pulmonary disease. The exacerbation rate was lower with the latter treatment. Exacerbations of chronic obstructive pulmonary disease (COPD) are associated with an accelerated decline in lung function, 1 – 3 impaired quality of life, 4 hospitalization, 5 and increased mortality. 6 COPD exacerbations are costly to health care systems. 7 Thus, prevention of exacerbations is a key goal in the management of COPD. 8 Inhaled long-acting bronchodilators not only control symptoms but also prevent COPD exacerbations. 9 – 12 Inhaled glucocorticoids are also known to reduce the frequency of exacerbations and have been studied in combination with inhaled long-acting beta-agonists (LABAs). 11 , 13 , 14 In one trial, the combination of a LABA plus an inhaled glucocorticoid (salmeterol–fluticasone) in fixed doses and . . .